SAMARTH LIFE SCIENCES PVT

SAMARTH has evolved into an innovative global life science company that explores, develops, manufactures and markets a broad range of life saving Critical Care drugs. The company has earned respect and customer loyalty by combining highly specialized skill sets - such as therapeutic area expertise and an understanding of global and local regulatory environments - with an uncommon dedication to providing superlative service. We aim at exponential growth through expansion in new therapeutic area and exploring new molecules. Our vision is to emerge as a globally renowned pharmaceutical enterprise by the acceptance & confidence of medical fraternity and quality of products with the highest level of operational excellence in all spheres. Samarth's unique focus is to bring innovative proprietary pharmaceuticals to market. We consider this approach the best way to serve the needs of patients, while addressing unmet medical needs. As Indian Pharma companies race to bring New Chemical Entities to the global marketplace, Samarth has established itself as a market driven; technology based company with a strong R & D base and is aiming at creating a niche market for products which are mostly import substitutes and life saving healthcare products. In it's pioneering spirit Samarth took a lead role in establishing a footprint in India in the year of 1963 from humble beginnings and has today developed into a multi dimensional, multi location pharmaceutical conglomerate. Together, our 750 specialized employees play an unequaled role in improving healthcare by providing a broad range of professional services, information & marketing life saving molecules to leading doctors in India. We have set up a marketing network that understands & responds to the customer's need and in the process, we also inculcate a high performance organizational culture. Our flagship brands ADRENOR, MUCOMIX, KENADION, DISTINON, UROTONE, CPRESSIN, INSED ATOMISER have gained wide credibility and acceptance among the medical fraternity and have become brand leaders in their respective segments. Exports are also thriving and our products find place on the shelves of markets in South America, U.K, South East Asian countries and many African states. Our products are manufactured under GMP facilities with raw materials imported from the best sources in the world. Samarth employs cutting edge technology for manufacturing and marketing its products. Armed with GMP and ISO 9001:2000 certification, Samarth is now looking beyond the horizon and planning forays into the developed western markets. An isolated and dedicated state-of-art production facility for development of oncology drugs with advanced liposomal technology has been commissioned. To enhance the capacities for meeting the growing demands the company has set up a separate unit for developing & manufacturing highly potent hormones. We take pride in featuring amongst one of the few companies that engage in manufacture of both pre-filled syringes & lyophilized products. Every step of manufacturing process & equipment used are compliant with the stringent WHO GMP requirements. As part of our expansion plans, we intend setting up a backward integration plant for bulk drugs as well as a new state of the art WHO GMP formulation unit. Successful operations, backed by strong infrastructure framework have accelerated Samarth's growth from oblivience to a turnover of US $15 million and shall continue to strive to produce quality drugs at affordable prices. We constantly challenge ourselves to be a step ahead in terms of quality and personalised services.